A Mediterranean infection re-visited by Cilia Vincenti, Albert
this is 1970 and Professor JV Zammit-Maempel, just before going on holiday for three weeks, sees a 22-year-old in a domiciliary consultation, with fever, constipation and a 
vague skin rash, and refers him to his ward at St Luke’s Hospital 
with a diagnosis of “?typhoid” and with instructions to start 
chloramphenicol intravenously. Chloramphenicol in those days 
was a very popular antibiotic – inexpensive and with the widest 
spectrum. It did however carry the rare risk of bone marrow 
damage and fatal aplastic anaemia. I do, in fact, remember 
carrying an autopsy on a young English woman who was given 
chloramphenicol in Spain, developing aplastic anaemia and 
subsequently transferred to London’s St George’s Hospital where 
she died, and where the case was presented at the physicians’ 
grand round.
Professor Zammit-Maempel maintained that no 
aplastic anaemia complication had ever been reported with 
chloramphenicol delivered intravenously, instead of orally, 
so a ten-day course of i.v. chloramphenicol was his favourite 
antibiotic regime. Back to the young man with the “?typhoid” 
diagnosis; I was the house officer, so we started the patient 
on the i.v. chloramphenicol, and Zammit-Maempel left on 
holiday without seeing this patient in the ward. A young senior 
registrar, recently returned from UK with his MRCP (not 
common in those days), had joined our firm and was now in 
charge of the ward.
The patient’s pyrexia soon resolved but after a few days it 
returned. Tests for typhoid were negative. The senior registrar 
discovered this young man had had a “hole-in-the heart” 
operation in London when he was a kid, and therefore suspected 
subacute bacterial endocarditis (SBE). Chloramphenicol was 
stopped and penicillin started. Fever resolved but returned 
again after a few days. Leishmaniasis was excluded when a bone 
marrow aspirate was reported negative. In desperation, a course 
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of tetracycline was instituted, but again, fever went down and 
returned after a few days. By this time the patient was emaciated 
and almost moribund, and Zammit-Maempel was due to return 
from holiday.
As soon as Zammit-Maempel returned, we got him to see 
this young man who had now been administered religious last 
rites. The senior registrar reminded Prof that he had referred 
this patient with a “?typhoid” diagnosis, and which had not 
been confirmed, SBE was suspected and adequate penicillin 
course given, Leishmaniasis had been excluded, and we were 
dealing with a rapidly deteriorating case of pyrexia of unknown 
origin. Zammit-Maempel leafed through the notes and declared 
he must be suffering from Leishmaniasis. The senior registrar 
protested that it had already been investigated and excluded. 
However, Zammit-Maempel insisted that he was suffering from 
Leishmaniasis – emphasising the two peaks every 24 hours 
on temperature chart, neutropenia and enlarged spleen. He 
reasoned that neutropenia and SBE don’t go together. Repeat 
bone marrow aspirate proved Zammit-Maempel right and i.v. 
antimony was started. 
Fast forward to mid-1980s, I am a consultant surgical 
pathologist in Winchester, southern England. Dr Anthony 
Galea-Debono and Mr Anthony Zammit are looking after 
a young haemophiliac with AIDS in Malta who’s got rectal 
bleeding from “?kaposi sarcoma” bowel lesions. One lesion is 
biopsied and referred to us. Microscopically the lesion consists of 
macrophages containing probable Donovan bodies. I sent some 
slides to Professor Sebastian Lucas in London (a histopathologist 
with a special interest in exotic infections) to confirm that it 
was Leishmaniasis, which he does. In the late 1980s, writing a 
chapter in “Advances in Histopathology”, Lucas uses this Maltese 
case (with due credits) to illustrate the emerging picture of 
Leishmaniasis complicating AIDS in the Mediterranean. 
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november is diabetes awareness month. WHO estimates that 8.5% of the global population suffers from diabetes.1 Diabetes is a chronic metabolic 
disease characterized by hyperglycemia resulting from 
abnormalities in insulin secretion, insulin action or 
insulin sensitivity. This chronic disease is associated with 
long term impairment, dysfunction and deterioration of 
different organs.
There are three types of diabetes:
Type 1 Diabetes in which the individual’s immune 
system destroys insulin-producing cells in the pancreas. 
This leads to a reduction in the capability of the body to 
produce insulin, requiring daily administration of insulin. 
The most common delivery devices are syringes, pens or 
pumps. Client education is vital and should encompass 
comprehensive information on caring for and using insulin, 
prevention, recognition and treatment of hypoglycaemia, 
adjustments of food intake and self-monitoring of blood 
glucose. Multiple daily injections is the most common 
method to attempt to mimick pancreatic insulin secretion. 
Type 2 Diabetes results from a progressive increase 
in resistance of the body to insulin. This type is most 
common in the middle-aged and elderly, however it 
is becoming more common in younger populations. 
Medications such as metformin and sulfonylureas are 
normally prescribed. However, insulin therapy is given 
to patients with severe diabetes. In the past insulin was 
used as a last resort, nevertheless nowadays insulin is 
prescribed earlier because of its benefits.
The last type of diabetes is Gestational Diabetes 
which is the onset of diabetes during pregnancy in an 
individual with no previous symptoms. This type is 
caused by insulin defiance during pregnancy and may 
lead to Type 2 Diabetes.
During the diabetes awareness month, MPSA 
launches a health campaign to further draw the attention 
of the public to possible symptoms. 
reference
1. http://www.who.int/mediacentre/factsheets/fs312/en/ 
Fast forward yet again to mid-1990s and I have returned 
to a consultant pathologist’s post in Malta. It is Christmas time 
and a young bachelor friend of ours returns from work overseas 
for the festive season. He is, however, ill-looking and says 
he’s pyrexic. A family doctor refers him to St Luke’s Hospital 
where a medical senior registrar suspects he’s very immune 
compromised, excludes Leishmaniasis with a negative bone 
marrow aspirate, and asks him whether he would take an HIV 
test. The patient is septicaemic and Professor CP Mallia warns 
his parents that he’s in danger of dying. Patient refuses to have 
an HIV test, saying that he would commit suicide if it were 
positive. I reassure him that there is now treatment, if positive. 
He improves with i.v. antibiotics and goes back overseas. A few 
days later he phones saying he’s feverish and weak again. I insist 
he gets to the nearest hospital immediately. There he goes into 
total system failure, almost dies in intensive care, he’s found 
to be HIV-positive, and Leishmaniasis is now diagnosed on a 
bone marrow aspirate. After a slow recovery, including renal 
dialysis for a couple of months, he returns to health after lengthy 
treatment for Leishmaniasis. He of course is still on HIV drugs, 
but is now in his early fifties, healthy and fit, and has held a 
number of very senior positions overseas. 
Addendum: the update on Cholesterol & Statins (Issue 4) 
did not clarify that the C-reactive protein (CRP) test referred 
to in cardiology circles is the high-sensitivity (hsCRP) variety.  
The normal CRP has little better sensitivity for inflammation 
than an ESR and is useless for atherosclerosis risk assessment.  
HsCRP is available in the profiles of some local private 
laboratories but apparently still unavailable at Mater Dei 
Hospital. 
Adverse events should be reported. Report adverse events to E.J. Busuttil Ltd. Tel: +356 21 44 7184
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